title: The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
abstract: In this review, we focus on the biologic advantages of dendritic cell-based vaccinations as a therapeutic strategy for cancer as well as preclinical and emerging clinical data associated with such approaches for glioblastoma patients.
authors.affiliation: Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Dana 2134, Boston, MA, 02215-5450, USA. David_Reardon@dfci.harvard.edu.
authors.forename: David A
authors.initials: DA
authors.lastname: Reardon
authors.affiliation: Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, FL, 32605, USA.
authors.forename: Duane A
authors.initials: DA
authors.lastname: Mitchell
mesh_terms: D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D002465:Cell Movement / Q000276:immunology; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism; D004195:Disease Models, Animal; D005909:Glioblastoma / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods; D014611:Vaccination
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines